Brief: DRI Healthcare Buys Synthetic Royalty Interest In Sales Of Sebetralstat For Hereditary Angioedema Treatment

DRI Healthcare Trust

04/11/2024 15:19

Nov 4 (Reuters) - Dri Healthcare Trust  DHT_u.TO :
    * DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A SYNTHETIC
ROYALTY INTEREST IN THE WORLDWIDE SALES OF SEBETRALSTAT FOR THE
TREATMENT OF HEREDITARY ANGIOEDEMA PLUS AN EQUITY INVESTMENT IN
KALVISTA PHARMACEUTICALS
    * DRI HEALTHCARE TRUST - ROYALTY INTEREST ACQUIRED FOR UP TO
$179
MILLION
    * DRI HEALTHCARE TRUST - FDA SETS PDUFA DATE FOR
SEBETRALSTAT ON
JUNE 17, 2025
    * DRI HEALTHCARE TRUST - INVESTS $5 MILLION IN KALVISTA
STOCK
    * DRI HEALTHCARE TRUST - KALVISTA ENTITLED TO $50 MILLION
MILESTONE PAYMENT

Source text:  ID:nCNWgtkDQa 
Further company coverage:  DHT_u.TO 

 ((Reuters.Briefs@thomsonreuters.com;))